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Abstract
Background: In recent decades, sporadic cases and outbreaks in humans of West Nile virus (WNV) infection have increased.
Serological diagnosis of WNV infection can be performed by enzyme-linked immunosorbent assay (ELISA), immunoflu-
orescence assay (IFA) neutralization test (NT) and by hemagglutination-inhibition assay. The aim of this study is to collect
updated information regarding the performance accuracy of WNV serological diagnostics.
Methodology/Principal findings: In 2011, the European Network for the Diagnostics of Imported Viral Diseases-
Collaborative Laboratory Response Network (ENIVD-CLRN) organized the second external quality assurance (EQA) study for
the serological diagnosis of WNV infection. A serum panel of 13 samples (included sera reactive against WNV, plus specificity
and negative controls) was sent to 48 laboratories involved in WNV diagnostics. Forty-seven of 48 laboratories from 30
countries participated in the study. Eight laboratories achieved 100% of concurrent and correct results. The main obstacle in
other laboratories to achieving similar performances was the cross-reactivity of antibodies amongst heterologous
flaviviruses. No differences were observed in performances of in-house and commercial test used by the laboratories. IFA
was significantly more specific compared to ELISA in detecting IgG antibodies. The overall analytical sensitivity and
specificity of diagnostic tests for IgM detection were 50% and 95%, respectively. In comparison, the overall sensitivity and
specificity of diagnostic tests for IgG detection were 86% and 69%, respectively.
Conclusions/Significance: This EQA study demonstrates that there is still need to improve serological tests for WNV
diagnosis. The low sensitivity of IgM detection suggests that there is a risk of overlooking WNV acute infections, whereas the
low specificity for IgG detection demonstrates a high level of cross-reactivity with heterologous flaviviruses.
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Introduction
West Nile virus (WNV) is a mosquito-transmitted flavivirus of
the family Flaviviridae [1]. It is maintained in a cycle between birds
and mosquitoes mostly belonging to the Culex genus [2].
Ochlerotatus, Culiseta, and Aedes mosquitoes are also competent
vectors [2]. Besides horses and humans several other mammals are
dead-end hosts of WNV [1,2,3].
About 80% of humans infected with WNV develop no or only
very mild symptoms. In about 20% of the cases patients develop
more severe symptoms such as fever, myalgia and lymphadenop-
athy. Furthermore, in small proportion of cases the infection
progresses to life-threatening neuroinvasive forms characterized by
meningitis, encephalitis and/or flaccid paralysis [1,4]. The risk of
developing lethal forms is increased in the elderly or in
immunocompromised patients [1,4].
WNV is the most widely spread flavivirus in temperate areas: it
has been isolated in parts of Europe, Middle East, Africa, Asia,
America and Australia, and migratory birds are responsible for the
dispersal of the virus [5,6,7]. WNV is also capable of causing
outbreaks of neuroinvasive infections, as demonstrated during
outbreaks in Romania in 1996 (about 800 cases), in Greece in
2010–2012 (more than 500 cases, still ongoing), several outbreaks
in the USA from 1999 to 2012, with over 15000 cases of
neuroinvasive infections and about 1500 deaths and the recently
confirmed WNV cases in Tunisia, in the Balkans and in Italy
[8,9,10,11,12].
Both serological and nucleic acid-based tests are available for
the diagnosis of WNV infections, but due to the short period of low
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viremia in humans, serological tests that detect virus-specific
antibodies are more reliable [1,13,14]. Following infection with
WNV, IgM antibodies are produced and can be detected within
4–7 days after exposure and may persist for about one year, while
IgG antibodies can be reliably detected from day 8 after infection
[15,16].
There are several types of serological tests routinely used for
WNV diagnostics: enzyme-linked immunosorbent assay (ELISA),
immunofluorescence assay (IFA), neutralization test (NT) and the
hemagglutination-inhibition assay. Commercial kits are available,
but several laboratories have also developed their own in-house
tests [1,13,17].
A major issue in WNV diagnostics is cross-reactivity with
antibodies against heterologous flaviviruses, e.g. dengue virus
(DENV), Japanese encephalitis virus (JEV), tick-borne encephalitis
virus (TBEV) or yellow fever virus, which is especially true for IgG
antibodies [18,19]. NT is considered the most specific technique,
but it is laborious, time-consuming and it can be performed only in
BSL-3 laboratories, while ELISA is rapid, reproducible and cost-
effective [1,16]. In 2005, the European Network for the
Diagnostics of Imported Viral Diseases-Collaborative Laboratory
Response Network (ENIVD-CLRN) organized the first external
quality assurance (EQA) study for WNV serological diagnostics to
assess the performances of laboratories involved in WNV
diagnostics [18]. The study revealed that the performance of
diagnostic tests varies amongst laboratories and that there is need
to improve them.
The aim of our study was therefore to update information on
performance accuracy of WNV serological diagnostic tests used by




Forty-eight laboratories involved in WNV serological diagnos-
tics were invited to participate in this second EQA study. The
study was organized by the ENIVD-CLRN network. The selection
of the invited laboratories was based on the register of ENIVD-
CLRN members as well as on their contributions to the literature
relevant to this topic. The participation in the study was open and
free of charge and included publication of the results in a
comparative and anonymous manner.
The following 47 laboratories participated in the study:
Albania: Institute Of Public Health, Tirana. Argentina: Instituto
de Virologı́a ‘‘. J.M. Vanella’’, Córdoba. Austria: Universität
Wien, Wien. Belgium: Institute of Tropical Medicine, Antwerpen.
Brazil: Instituto Evandro Chagas, Ananindeua. Bulgaria: National
Center of Infectious and Parasitic Diseases, Sofia. Costa Rica:
CNRV Inciensa, Cartago. Cuba: Institute for Tropical Medicine
‘‘Pedro Kourı́’’, Havana City. France 1: IRBA-IMTSSA Unité de
Virologie, Marseille. France 2: LNR/LCR West Nile UMR1161,
Maisons-Alfort. Germany 1: EUROIMMUN AG, Lübeck.
Germany 2: Friedrich-Loeffler-Institut, Greifswald - Insel Riems.
Germany 3: Institut für Mikrobiologie der Bundeswehr Zentral-
bereich Diagnostik, München. Germany 4: Institut für virologie,
Hannover. Germany 5: Niedersächsisches Landesuntersuchung-
samt, Hannover. Greece: Aristotle University of Thessaloniki,
Thessaloniki. Iran: Pasteur Institute of Iran, Tehran. Italy 1:
Amedeo Hospital, Torino. Italy 2: Istituto Superiore di Sanità,
Rome. Italy 3: Lazzaro Spallanzani, Rome. Italy 4: Molecular
Biology Section Army Medical and Veterinary Research Center,
Rome. Italy 5: Istituto G. Caporale, Teramo. Latvia: Infectology
Center of Latvia, Riga. Mexico: Lab. de Virus Hemorrágicos.
Depto. Enfermedades Emergentes y Urgencias. Norway: Norwe-
gian Institute of Public Health, Oslo. Portugal: National Institute
of Health, Águas de Moura. Republic of Macedonia: Institute of
Public Health, Skopje. Romania: Cantacuzino Institute, Buchar-
est. Russia: Central Research Institute of Epidemiology, Moscow.
Saudi Arabia 1: Jeddah Regional Laboratory, Jeddah. Saudi
Arabia 2: King Abdulaziz University Hospital, Jeddah. Senegal:
Institut Pasteur, Dakar. Slovenia: University of Ljubljana,
Ljubljana. South Africa 1: NHLS, Bloemfontein. South Africa 2:
National Institute for Communicable Diseases, Johannesburg.
Spain 1: Instituto de Salud Carlos III, Majadahonda. Spain 2:
Clinic i Provincial de Barcelona, Barcelona. Spain 3: Investigadora
Campus de Bellaterra, Barcelona. Sweden: Swedish Institute for
Infectious disease control, Solna. Switzerland 1 : Spiez Laboratory,
Spiez. Switzerland 2: Zentrum für Labormedizin, St Gallen.
Switzerland 3: University Hospital of Geneva, Geneva. Turkey:
National Public Health Agency, Ankara. The Netherlands 1:
Erasmus MC, Rotterdam. The Netherlands 2: National Institute
of Public Health and the Environment (RIVM), Bilthoven. U.K. 1:
Health Protection Agency, London. U.K. 2: Animal Health and
Veterinary Laboratories Agency, New Haw Surrey.
Preparation and distribution of test samples
The preparation and distribution of the panels were carried out
as previously described for the first EQA study on WNV
diagnostics [18]. The instructions provided to the participants
were also the same as for the previous EQA [18]. The test panel
consisted of 13 different sera, including sera reactive against WNV
as positive controls, sera reactive against heterologous flaviviruses
as specificity controls and negative control sera.
The exact composition of the test panel was:
N 4 serial dilution of WNV BM140375 IgM/IgG positive serum
(1:1, 1:2, 1:4, 1:8)
N one WNV BM141170 IgM negative/IgG positive serum
N one WNV WM(67/11) IgM low positive/IgG positive serum
N one WNV Greece (genetic lineage II) IgM low positive/IgG
positive serum
N one DENV IgM negative/IgG positive serum
N one JEV IgM negative/IgG positive serum
Author Summary
West Nile virus (WNV) is mantained in the environment in a
cycle between mosquitoes and birds. The virus has been
isolated on almost all the continents, and several migratory
bird species are primarily responsible for virus spread and
dispersal. Humans acquire the infection through WNV-
infected mosquito bites. Although most infected humans
remain symptoms-free, in a minority of cases (especially in
the elderly or immunocompromised patients) the infection
can develop into a neuroinvasive form causing life-
threatening encephalitis and threatening meningitis.
Diagnosis of WNV is based primarily on serological tests,
i.e. the detection of the virus-specific antibodies in human
serum. Our aim was to collect updated information
regarding the performance accuracy of WNV serological
diagnostic tests used by laboratories involved in WNV
diagnostics, in order to identify the strengths and
weaknesses of diagnostic techniques in each laboratory.
The performance of diagnostic tests varied among the
laboratories, indicating that there is still a need to improve
test procedures and to harmonize protocols.
Accuracy Study on West Nile Virus Diagnostics
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N one TBEV IgM negative/IgG positive serum
N one Usutu virus (USUV) IgM negative/IgG positive serum
N 2 negative controls: one provided by EUROIMMUN
(containing rheumatoid factor) and one in house negative
control.
The DENV and the WNV plasma sera were obtained from
plasmapherese centres from US and Costa Rica and were
purchased from SeraCare Life Sciences, Milford, MA, USA. For
TBEV and JEV the sera came from vaccinees, while for USUV
the sample was provided by reference laboratories of ENIVD-
CLRN network routine diagnostics.
Ethics statement
All subjects provided informed oral consent. All samples taken
from the collections were anonymized.
Evaluation of participants’ results
Two criteria were selected to evaluate the proficiency of each
laboratory: 1) laboratories had to identify the seven WNV-positive
serum samples irrespective of differentiation between IgM and
IgG, i.e. if at least one of the test gave a positive result 1 point was
assigned, and 2) the four serum samples containing cross-reactive
antibodies to the heterologous flaviviruses (DENV, JEV, TBEV,
USUV) and the two negative controls should not give a positive
result and/or should be recognized as being unspecific. Equivocal
or borderline results with the six non-WNV serum samples were
interpreted as negative. False positive and false negative results
were evaluated as incorrect and attributed a score of 0 points. The
maximum score for each laboratory is 13 points (indicated as
100%), indicating that all diagnostic results were correct.
For each of the 13 serum samples, the score was assigned using
identical criteria, allowing the percentage of laboratories giving
correct results for each specific serum to be determined.
In order to be consistent and to make the results comparable,
scoring criteria identical to those used during the first EQA study
for the serological diagnosis of WNV infection were used [18]. The
performances of the diagnostic tests with regard to IgM and IgG
results were considered separately in order to give additional
information concerning the quality of the laboratory diagnostics.
Data were collected using Microsoft Excel (Microsoft Corp.,
Bellingham, WA, USA) and analysed using SPSS 14.0 for
Windows. Results with respect to categorized variables were
analysed by the chi-square test. A p-value,0.05 was considered to
be statistically significant.
Results and Discussion
Participation to the study
Forty seven of 48 invited laboratories participated in the study
(98% response rate). A total of 30 countries were involved,
including 2 from Europe, 5 from America, 2 from Asia and 2
from Africa (see materials and methods section). A total of 51
tested panels were received for IgM and/or IgG detection because
four laboratories sent two tested panels using both ELISA and IFA
or NT test.
Overall proficiency of the participants
Tables 1, 2 and 3 summarize the results obtained using ELISA,
IFA and NT as detection method, respectively, and are sorted by
percentage of correct results for each laboratory.
The most widely used serological diagnostic test was ELISA,
performed in 35 of 51 tested panels (69%), followed by IFA (in 11
of 51 tested panels, 22%) and NT (in 5 of 51 tested panels, 9%).
Four laboratories using ELISA detected only IgM antibodies and
no IgG antibodies.
In 37 of the 51 tested panels (73%) a commercial test was used,
whereas an in-house test was used in the remaining 14 tested panes
(27%).
According to the criteria given, heterogeneous scores were
observed among the in-house and commercial tests used by the
laboratories. Nevertheless, the scoring for in-house tests was the
same as for commercial tests, ranging overall from 54 to 100%. In
accordance with the first WNV EQA and as well as other EQA
studies for the serological detection of DENV and hantavirus
infections, there were no statistically significant differences in
scores between laboratories using commercial or in-house assays
[18,19,20,21]. Interestingly, several laboratories using the same
commercial kit but obtained different results (e.g. the panels 19
and 29 used ELISA kit ‘‘F’’ and gained 100% scores, and panels 4,
18, 26 and 30 also used ELISA kit ‘‘F’’ but gained 62% scores) as
observed in the first EQA study [18]. This may highlight the need
for some laboratories to perform correctly the test. However, in
the panels 19 and 29 additional tests were performed with the
negative controls which permitted to identify the false positive as
heterologous flaviviruses (marked as +* in the tables). This
indicates that the performance of additional tests for flaviviruses
may help in interpreting the results, especially if not so high or
borderline antibody-titres have been obtained.
No significant differences have been observed in performances
among the different continents and among WNV-free and WNV-
endemic countries. In countries reporting several panels (Spain,
Germany and Italy) some slight differences exists, due also to the
different methods used.
The best scores were obtained in eight tested panels (32, 19, 31,
29b, 38, 17, 26b and 42) where 100% of the diagnostic results
were correct (13 out of 13 points) (Tables 1, 2 and 3). Of these
eight tested panels, ELISA was performed in five, IFA in one and
NT in two. In the other tested panels, the percentage of correct
results varied from 54 to 92% (from 7 to 12 of 13 points). The
major impediment preventing other laboratories from reaching
the maximum level of performance was the cross-reactions with
antibodies specific for heterologous flaviviruses, giving a high
proportion of false-positives, especially for IgG detection. This is
particularly true for cross-reactivity with DENV antibodies (serum
sample #9) where only 21 of the 47 tested panels for IgG (44%)
reported a correct result. Regarding the heterologous flaviviruses,
(JEV, TBEV and USUV), correct results were reported in 37, 34
and 31 of the 47 tested panels for IgG respectively (equating to
79%, 72% and 66%). A statistically significant difference exists
between the proportion of correct results for DENV and for the
other three flaviviruses (p,0.05). For the serum sample #2
(negative control) a correct result was reported in 36 of the 51
tested panels (71%). The high number of incorrect results with this
negative control could be due to the presence of auto-antibodies
that were reactive in the WNV serological tests. Serum sample #8
represents the genetic lineage II strain of WNV and was correctly
detected in 40 of the 51 panels (78%). The WNV lineages I and II
have about 30% of nucleotide divergence and showed antigenic
variability, as observed in in cross neutralization analyses and
monoclonal antibody binding assays [22,23,24,25]. The antibody
titre of the lineage II reactive serum was 1:100 for IgM, 1:1000 for
IgG. Serum samples #3 and #1 (two WNV genetic lineage I
strains) were correctly detected in 100% and 98% of the panels,
respectively, giving the highest rate of correct results. Serum
samples #12, #5, #7 and #6 were 4 serial dilutions of a WNV
genetic lineage I strain, and results for these serum samples showed
Accuracy Study on West Nile Virus Diagnostics
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a decrease in sensitivity with increasing dilution (Tables 1, 2 and
3).
Performances of the different serological tests
Considering only ELISA, 29 of 35 (83%) tested panels were
obtained using a commercial test whereas 6 of 35 (17%) tested
panels were obtained using an in-house test.
For IFA, 8 of 11 tested panels were obtained using a commercial
test (73%) whereas 3 of 11 tested panels (27%) were obtained using
an in-house test. All NT were in-house tests.
Scores ranged from 54 to 100% in tested panels using ELISA,
from 62 to 100% for tested panels using IFA and from 62 to 100%
for tested panels using NT. No statistically significant difference
was observed in the scores of the three different serological tests.
Considering the scores related to each serum sample, it is
possible to draw conclusions about the sensitivity and specificity of
the different tests, particularly when comparing ELISA and IFA
results, as there were only 5 laboratories performing NT.
The evaluation of sensitivity (capacity to detect true positives)
involves the serum samples positive for WNV (serum samples
#12, #5, #7, #6, #1, #3, #8 in tables 1, 2 and 3). For ELISA
the sensitivity was 54% and 87% with respect to IgM and IgG
detection, while for IFA the sensitivity was 45% and 86% with
respect to IgM and IgG detection. One difference in sensitivity
between ELISA and IFA is observed for the detection of the WNV
lineage II. IFA seems to be more sensitive than ELISA for the
detection of WNV lineage II (91 and 77% respectively), although,
as no statistically significant difference was observed, this is only a
tendency.
The evaluation of specificity (capacity to detect the true
negatives) involves the serum samples negative for WNV (serum
samples #9, #4, #14, #11, #2, #13 in tables 1, 2 and 3). For
ELISA the specificity was 94% and 64% with respect to IgM and
IgG detection, while for IFA the specificity was 99% and 85% with
respect to IgM and IgG detection The IFA was more specific than
ELISA in detecting IgG antibodies (p-value,0.05).
Although only 5 laboratories performed NT, it is interesting that
low sensitivity was observed even for the highest concentrations of
the WNV serum (Table 3).
Performances of the tests with respect to IgM and IgG
detection
As the test cannot distinguish between IgM and IgG antibodies,
NT is excluded from this analysis.
A result for IgM detection was reported for 46 tested panels.
The percentage of IgM antibodies correctly detected by the
serological tests was 71%, with a sensitivity of 50% and a
specificity of 95%. The low sensitivity for IgM detection can be
explained mainly by the low detection of IgM antibodies of the
WNV lineage II (serum sample #8): correct results were reported
only in 5 of 46 tested panels.
As previously described in other EQA studies, such a low
sensitivity for IgM detection leads to a risk that acute WNV
infections can be overlooked [18,21], and this can be especially
dangerous for infections with the lineage II, which has been
increasingly isolated and involved in outbreaks in recent years
[26].
A result for IgG detection was reported for 42 tested panels. The
percentage of IgG correctly detected by the serological tests was
78%, with an overall sensitivity of 86% and a specificity of 69%.
The low specificity for IgG detection can be explained mainly by
the cross-reactivity of the test with antibodies of heterologous
flaviviruses, especially DENV (serum sample #9): correct results
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cross-reactivity is a well-known problem for serological assays
especially among flaviviruses [17,18,19,20].
Comparison between first and second EQA study of WNV
serological diagnostics
In this second study, the number of participating laboratories
was almost double that of the first study (47 and 27, respectively)
[18]. In addition, coverage has increased, with 30 countries being
involved in this second study compared to 20 in the first [18].
The number of serum samples included in the panel for the
second study was increased from 10 to 13. The serum sample
positive for WNV strain belonging to the genetic lineage II, the
four serum samples in serial dilution and serum sample positive for
JEV and USUV were included in this second study. There was no
improvement in the number of laboratories that achived the 100%
score in this second study compared to the first [18]. This could be
due to difficulties in detecting the WNV lineage II and/or in
detecting the higher dilutions of the WNV serum and/or the high
level of cross-reactivity with DENV antibodies.
The percentage of IgM antibodies correctly detected in this
study increased from 62% to 71% while the percentage of IgG
correctly detected decreased from 88% to 78%.
A total of 16 laboratories participated in both studies. Among
these, five laboratories increased their score, ten laboratories
decreased their score and one laboratory had the same score.
However, as the number and the nature of serum samples were
different in these two studies, comparisons of performances
between the two studies need to be considered carefully.
Finally, as previously described, uneven performances and
results have been obtained among laboratories using the same test
[18].
The results of this second EQA study on WNV serological
diagnostics demonstrate that there is still need to improve tests
(either in-house or commercial), and to improve the test
procedures used by laboratories.
Contrasting test performances were observed with respect to
IgM detection (low sensitivity), or IgG detection (low specificity).
Reliable assays for IgM detection are crucial for the diagnosis of
acute or recent infections in humans and therefore their
development is of first priority. Increasing of specificity for IgG
detection is the second objective improving the diagnostics of
WNV infection.
The results of an EQA study allow all participant laboratories to
identify problems and to improve their performances, as well as to
receive feedback via a final anonymized report and guidance upon
request from the ENIVD-CLRN network. To improve diagnostic
tests performances, for any positive results identified by ELISA or
IFA, a second confirmatory more specific test should be applied,
e.g. NT. Of remarks, in our study only five laboratories performed
a NT test for WNV diagnosis. Moreover, due to the persistence of
IgM antibodies [14,15], a pair of samples should be tested for all
suspected cases combined with IgG avidity test to distinguish
among recent and past WNV infections [27].
Due to the cross-reactivity with heterologous flaviviruses, other
diagnostic tests with heterologous flaviviruses should be performed
to better identify false-positive results.
The broadening of the number of participants for this second
EQA study compared to the first gave us a better overview of the
strengths and weaknesses regarding the serological diagnosis of
WNV infection. The increasing spread of WNV lineage II in
Europe should be taken into account when establishing new
diagnostic assays and evaluating performance in the future.
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(EUPHEM Cohort 2), Aftab Jasir and Steen Ethelberg for critical reading
of the manuscript and administrative-technical support.
Author Contributions
Conceived and designed the experiments: ODM MN. Performed the
experiments: AT. Analyzed the data: AP VS AS MN ODM. Contributed
reagents/materials/analysis tools: AP VS. Wrote the paper: AS.
References
1. De Filette M, Ulbert S, Diamond M, Sanders NN (2012) Recent progress in
West Nile virus diagnosis and vaccination. Vet Res 43: 16–30.
2. Goddard LB, Roth AE, Reisen WK, Scott TW (2002) Vector competence of
California mosquitoes for West Nile virus. Emerg Infect Dis 8: 1385–1391.
3. Rossi SL, Ross TM, Evans JD (2010) West Nile virus. Clin Lab Med 30: 47–65.
4. Hayes EB, Sejvar JJ, Zaki SR, Lanciotti RS, Bode AV, et al. (2005) Virology,
pathology, and clinical manifestations of West Nile virus disease. Emerg Infect
Dis 8: 1174–1179.
5. Hayes EB, Komar N, Nasci RS, Montgomery SP, O’Leary DR, et al. (2005)
Epidemiology and transmission dynamics of West Nile virus disease. Emerg
Infect Dis 8: 1167–1173.
6. Reiter P (2010) West Nile virus in Europe: understanding the present to gauge
the future. Euro Surveill 15: 19508.
7. Kilpatrick AM (2011) Globalization, land use, and the invasion of West Nile
virus. Science 334: 323–327.
8. Tsai TF, Popovici F, Cernescu C, Campbell GL, Nedelcu NI (1998) West Nile
encephalitis epidemic in southeastern Romania. Lancet 352: 767–771.
9. Papa A (2012) West Nile virus infections in Greece: an update. Expert Rev Anti
Infect Ther 10: 743–750.
10. European Centre for Diseases Prevention and Control (ECDC) (2012) West Nile
fever maps. Available: http://ecdc.europa.eu/en/healthtopics/west_nile_fever/
West-Nile-fever-maps/Pages/index.aspx
11. Centre for Diseases Prevention and Control (CDC), Division of Vector-Borne
diseases (2012) West Nile virus. Available: http://www.cdc.gov/ncidod/dvbid/
westnile/surv&control_archive.htm
12. EpiSouth Weekly (2012) Epi Bulletin 238. Available: http://www.
episouthnetwork.org/sites/default/files/bulletin_file/eweb_238_11_10_12.pdf.
13. Linke S, Mackay WG, Scott C, Wallace P, Niedrig M (2011) Second external
quality assessment of the molecular diagnostic of West Nile virus: are there
improvements towards the detection of WNV? J Clin Virol 52: 257–260.
14. Tardei G, Ruta S, Chitu V, Rossi C, Tsai TF, et al. (2000) Evaluation of
immunoglobulin M (IgM) and IgG enzyme immunoassays in serologic diagnosis
of West Nile Virus infection. J Clin Microbiol 38: 2232–2239.
15. Roehrig JT, Nash D, Maldin B, Labowitz A, Martin DA, et al. (2003) Persistence
of virus-reactive serum immunoglobulin m antibody in confirmed west nile virus
encephalitis cases. Emerg Infect Dis 9: 376–379.
16. Niedrig M, Sonnenberg K, Steinhagen K, Paweska JT (2007) Comparison of
ELISA and immunoassays for measurement of IgG and IgM antibody to West
Nile virus in human sera against virus neutralisation. J Virol Method 139: 103–
105.
17. Papa A, Karabaxoglou D, Kansouzidou A (2011) Acute West Nile virus
neuroinvasive infections: cross-reactivity with dengue virus and tick-borne
encephalitis virus. J Med Virol 83: 1861–1865.
18. Niedrig M, Donoso Mantke O, Altmann D, Zeller H (2007) First international
diagnostic accuracy study for the serological detection of West Nile virus
infection. BMC Infect Dis 7: 72–76.
19. Donoso Mantke O, Lemmer K, Biel SS, Groen J, Schmitz H, et al. (2004)
Quality control assessment for the serological diagnosis of dengue virus
infections. J Clin Virol 29: 105–112.
20. Donoso Mantke O, Schmitz H, Zeller H, Heyman P, Papa A, et al. (2005)
Quality assurance for the diagnostics of viral diseases to enhance the emergency
preparedness in Europe. Euro Surveill 10: 102–106.
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